Scientists have discovered a new antibiotic, teixobactin, that can kill serious infections in mice without encountering any detectable resistance, offering a potential new way to get ahead of dangerous evolving superbugs.
Researchers said the antibiotic, which has yet to be trialled in humans, could one day be used to treat drug-resistant infections caused by the superbug MSRA, as well as tuberculosis, which normally requires a combination of drugs that can have adverse side effects.
“The discovery of this novel compound challenges long-held scientific beliefs and holds great promise for treating an array of menacing infections,” said Kim Lewis, a professor at Northeastern University in the United States and co-founder of the NovoBiotic Pharmaceuticals, which has patented teixobactin.
Lewis worked with researchers at Germany’s University of Bonn and with Britain’s Selcia Limited, and the finding was published in the journal Nature on Wednesday. More